Nepsis Inc. Sells 212,033 Shares of Health Catalyst, Inc. $HCAT

Nepsis Inc. cut its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 12.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,513,032 shares of the company’s stock after selling 212,033 shares during the period. Health Catalyst comprises 1.4% of Nepsis Inc.’s investment portfolio, making the stock its 23rd largest position. Nepsis Inc.’s holdings in Health Catalyst were worth $4,312,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Cresset Asset Management LLC acquired a new stake in Health Catalyst in the second quarter valued at approximately $39,000. Divergent Planning LLC acquired a new position in shares of Health Catalyst during the second quarter worth $45,000. Focus Partners Wealth bought a new position in shares of Health Catalyst in the 1st quarter valued at $46,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Health Catalyst during the 2nd quarter valued at $73,000. Finally, The Manufacturers Life Insurance Company grew its position in Health Catalyst by 19.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock worth $100,000 after acquiring an additional 4,341 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $2.47 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88. Health Catalyst, Inc. has a fifty-two week low of $2.02 and a fifty-two week high of $7.25. The company has a 50 day simple moving average of $2.54 and a two-hundred day simple moving average of $3.07. The company has a market capitalization of $174.70 million, a PE ratio of -1.55 and a beta of 1.69.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Monday, November 10th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.01. Health Catalyst had a negative net margin of 34.05% and a negative return on equity of 6.67%. The company had revenue of $76.32 million for the quarter, compared to analyst estimates of $75.05 million. Research analysts anticipate that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Insider Transactions at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 27,425 shares of Health Catalyst stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $2.64, for a total value of $72,402.00. Following the completion of the sale, the general counsel directly owned 100,000 shares in the company, valued at approximately $264,000. The trade was a 21.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Julie Larson-Green sold 47,997 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $2.67, for a total value of $128,151.99. Following the completion of the transaction, the director directly owned 73,573 shares in the company, valued at approximately $196,439.91. This trade represents a 39.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

HCAT has been the subject of several research reports. Citigroup dropped their target price on Health Catalyst from $3.25 to $2.75 and set a “neutral” rating for the company in a research report on Friday. Evercore ISI dropped their price objective on shares of Health Catalyst from $4.00 to $3.00 and set an “in-line” rating for the company in a report on Wednesday, October 8th. UBS Group reissued an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. William Blair restated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. Finally, KeyCorp cut their price target on shares of Health Catalyst from $5.00 to $4.00 and set an “overweight” rating on the stock in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Health Catalyst has an average rating of “Hold” and a consensus price target of $4.32.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.